Alexandria Real Estate Equities (NYSE: ARE), the largest publicly traded owner of life-science lab space in the country, reported a second-quarter 2026 net loss of $0.43 per diluted share and adjusted funds from operations (FFO) of $1.73 per share, as the Pasadena, Calif.-based REIT booked $222.5 million in real estate impairment charges even as leasing activity ticked higher, according to the company’s Aug. 3 earnings release. Total revenue fell to $662.8 million from $762.0 million a year earlier, and adjusted FFO per share declined from $2.33 in the second quarter of 2025.
The results land as the life-science real estate sector continues to work through a multi-year stretch of oversupply and softer tenant demand that followed the pandemic-era lab-space building boom. Rents have cooled and vacancies have risen across the industry’s core clusters β Boston/Cambridge, San Diego and the San Francisco Bay Area β as biotech funding normalized and developers delivered speculative space faster than tenants could absorb it. Alexandria, as the sector’s bellwether, has become a proxy for how quickly that imbalance is working itself out.
Occupancy and Leasing
Alexandria’s operating occupancy stood at 86.9% as of June 30, 2026, or 90.9% including space under signed leases that have not yet commenced. Same-property net operating income fell 10.6% year over year (down 8.6% on a cash basis), which the company attributed to previously disclosed large lease expirations across more than 900,000 rentable square feet over the past two quarters.
On the leasing side, the company signed 1,038,917 rentable square feet (RSF) of leases in the quarter, up 60% from the first quarter and roughly 87,000 RSF above its trailing five-quarter average. Alexandria said 57% of annual rental revenue comes from investment-grade or publicly traded large-cap tenants, and 80% comes from its “Megacampus” cluster properties. In one notable deal, the company leased 159,947 RSF at 3000 Minuteman Road in Greater Boston to an advanced-technology tenant rather than a traditional lab user β a pivot the company said cut roughly $80 million from that project’s construction budget, illustrating how landlords are adapting space plans amid softer lab demand.
Development, Dispositions and Balance Sheet
During the first half of 2026, Alexandria placed into service a 426,927-square-foot development at 4135 Campus Point Court in San Diego, fully leased to Bristol Myers Squibb, adding $57 million in incremental annual NOI. The company’s active pipeline includes another $42 million of expected NOI (174,662 RSF, 84% leased) due in the second half of 2026, and a 2027β2028 pipeline totaling 1,258,004 RSF and $93 million of expected NOI, currently 68% pre-leased.
Alexandria is also leaning on asset sales to shore up its balance sheet, guiding to roughly $2.9 billion in 2026 dispositions at the midpoint. As of the release date, it had completed $170.4 million, including a $163 million land sale at 3825/3875 Fabian Way in Palo Alto, with $1.16 billion more pending. The company reported $3.60 billion of total liquidity and extended its $5.0 billion unsecured credit line to January 2032 at a reduced rate. Net debt and preferred stock to adjusted EBITDA stood at 7.0x on an annualized basis, with a year-end target range of 5.6x to 6.2x. The board declared a quarterly dividend of $0.72 per share, a 5.4% yield as of quarter-end.
Guidance
Alexandria maintained its full-year 2026 guidance, projecting adjusted FFO of $6.35 to $6.45 per share (midpoint $6.40), year-end operating occupancy of 86.2% to 87.8%, and same-property NOI change of -10.5% to -8.5%. Executive Chairman Joel S. Marcus and CEO Peter M. Moglia lead the company; the release itself did not include direct executive commentary, with color instead expected on the company’s Aug. 4 earnings call.
What It Means
The facts: revenue and FFO per share both declined year over year, occupancy softened, and a large impairment charge drove the GAAP net loss β while leasing volume improved sequentially and full-year guidance held steady. The company has attributed the NOI decline to known lease expirations rather than a broader collapse in demand, and it points to its investment-grade tenant base and long-duration debt as buffers. Read together, the quarter reads as a REIT managing through a sector-wide correction β leaning on dispositions and refinancing to protect liquidity β rather than one facing a demand shock unique to Alexandria.
What to Watch
Investors will watch whether Alexandria hits its $2.9 billion disposition target and whether leverage actually declines toward its 5.6x-6.2x year-end goal. Also worth tracking: whether more landlords follow Alexandria’s Boston pivot toward non-lab, technology tenants in redevelopment projects, and whether life-science leasing volume continues its sequential improvement into the back half of 2026 or stalls again. For more coverage of REIT earnings and commercial property trends, see RealtyWire’s commercial real estate section, including recent results from Ares Commercial Real Estate and American Healthcare REIT.
